🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Impact of Uterine and Ovarian Vessel Occlusion on Blood Loss in High Burden Minimally Invasive Myomectomy.

RecruitingNAAges 18 Years - anyFemaleThe University of Texas Health Science Center, Ho…
NCT07182045 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study hypothesizes that temporary bilateral uterine and utero-ovarian artery occlusion with laparoscopic clamps at time of minimally invasive myomectomy will lead to a decreased blood loss at time of myomectomy compared to minimally invasive myomectomy without temporary occlusion.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient undergoing minimally invasive myomectomy with either a single intramural or Submucosal fibroid =/\>5cm or * Patients undergoing minimally invasive Myomectomy with =/\> 5 fibroids Exclusion Criteria: * Pregnancy, * Age \<18yo, * Patients undergoing concomitant surgery such as endometriosis surgery, * Suspected malignancy
💊

What it tests

  • Temporary clamping of uterine and ovarian vessels
📍

Where

1 site
Memorial Hermann Hospital
Houston, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy